{"id":"mmh-map","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, MMH-MAP prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the inhibition on T cells and enhancing the immune response against cancer cells.","oneSentence":"MMH-MAP is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:56.517Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT04295681","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2019-12-12","conditions":"Cognitive Disorders","enrollment":246},{"nctId":"NCT04552041","phase":"PHASE3","title":"Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2020-12-03","conditions":"Vascular Dementia","enrollment":406},{"nctId":"NCT04569357","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2020-11-20","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":363},{"nctId":"NCT03815292","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke","status":"COMPLETED","sponsor":"Materia Medica Holding","startDate":"2018-10-19","conditions":"Mild Cognitive Impairment, Ischemic Stroke","enrollment":276}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prospekta"],"phase":"phase_3","status":"active","brandName":"MMH-MAP","genericName":"MMH-MAP","companyName":"Materia Medica Holding","companyId":"materia-medica-holding","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MMH-MAP is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}